{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:55:40Z","timestamp":1774529740162,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL160892 and R01HL172993"],"award-info":[{"award-number":["R01HL160892 and R01HL172993"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"DOI":"10.1007\/s11897-026-00754-z","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T09:08:56Z","timestamp":1774516136000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiorenal Biomarkers and their Implications in Prognosis and Treatment Response of Transthyretin Cardiac Amyloidosis"],"prefix":"10.1007","volume":"23","author":[{"given":"Artrish","family":"Jefferson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka","family":"Narvekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethany","family":"Roehm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Toto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin L.","family":"Grodin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"issue":"9","key":"754_CR1","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jama.2024.0442","volume":"331","author":"FL Ruberg","year":"2024","unstructured":"Ruberg FL, Maurer MS. Cardiac amyloidosis due to transthyretin protein: a review. JAMA. 2024;331(9):778\u201391.","journal-title":"JAMA"},{"issue":"8","key":"754_CR2","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.2215\/CJN.08720811","volume":"7","author":"L Lobato","year":"2012","unstructured":"Lobato L, Rocha A. Transthyretin amyloidosis and the kidney. Clin J Am Soc Nephrol. 2012;7(8):1337\u201346.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"754_CR3","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jaccao.2021.06.006","volume":"3","author":"JM Griffin","year":"2021","unstructured":"Griffin JM, Rosenthal JL, Grodin JL, Maurer MS, Grogan M, Cheng RK. ATTR amyloidosis: current and emerging management strategies: JACC: cardioOncology state-of-the-art review. JACC CardioOncol. 2021;3(4):488\u2013505.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"754_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jamacardio.2024.4578","volume":"10","author":"A Ioannou","year":"2025","unstructured":"Ioannou A, Razvi Y, Porcari A, Rauf MU, Martinez-Naharro A, Venneri L, et al. Kidney Outcomes in Transthyretin Amyloid Cardiomyopathy. JAMA Cardiol. 2025;10(1):50\u20138.","journal-title":"JAMA Cardiol"},{"issue":"10","key":"754_CR5","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrneph.2016.113","volume":"12","author":"JC Schefold","year":"2016","unstructured":"Schefold JC, Filippatos G, Hasenfuss G, Anker SD, von Haehling S. Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol. 2016;12(10):610\u201323.","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"754_CR6","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1016\/j.jacc.2005.11.084","volume":"47","author":"GL Smith","year":"2006","unstructured":"Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47(10):1987\u201396.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"754_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.102766","volume":"14","author":"P Garc\u00eda-Pav\u00eda","year":"2026","unstructured":"Garc\u00eda-Pav\u00eda P, Witteles RM, Damy T, Fontana M, Palladini G, Tsujita K, et al. Monitoring Disease Progression in Patients With Transthyretin Amyloid Cardiomyopathy. JACC Heart Fail. 2026;14(1):102766.","journal-title":"JACC Heart Fail"},{"issue":"2","key":"754_CR8","first-page":"300","volume":"6","author":"BW Sperry","year":"2024","unstructured":"Sperry BW, Sultan MB, Gundapaneni B, Tai SS, Witteles RM. Effect of Tafamidis on renal function in patients with transthyretin amyloid cardiomyopathy in ATTR-ACT. JACC: CardioOncology. 2024;6(2):300\u20136.","journal-title":"JACC: CardioOncology"},{"issue":"5","key":"754_CR9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1159\/000522370","volume":"146","author":"R Fenoglio","year":"2022","unstructured":"Fenoglio R, Baldovino S, Barreca A, Bottasso E, Sciascia S, Sbaiz L, et al. Renal involvement in transthyretin amyloidosis: the double presentation of transthyretin amyloidosis deposition disease. Nephron. 2022;146(5):481\u20138.","journal-title":"Nephron"},{"issue":"19","key":"754_CR10","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.jacc.2008.07.051","volume":"52","author":"C Ronco","year":"2008","unstructured":"Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527\u201339.","journal-title":"J Am Coll Cardiol"},{"key":"754_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11237041","author":"AC Mitsas","year":"2022","unstructured":"Mitsas AC, Elzawawi M, Mavrogeni S, Boekels M, Khan A, Eldawy M, et al. Heart failure and cardiorenal syndrome: a narrative review on pathophysiology, diagnostic and therapeutic regimens-from a cardiologist\u2019s view. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11237041.","journal-title":"J Clin Med"},{"issue":"1","key":"754_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1053\/j.ackd.2012.10.005","volume":"20","author":"DN Cruz","year":"2013","unstructured":"Cruz DN. Cardiorenal syndrome in critical care: the acute cardiorenal and renocardiac syndromes. Adv Chronic Kidney Dis. 2013;20(1):56\u201366.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"6","key":"754_CR13","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1161\/01.CIR.83.6.1849","volume":"83","author":"KT Weber","year":"1991","unstructured":"Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83(6):1849\u201365.","journal-title":"Circulation"},{"issue":"6","key":"754_CR14","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1152\/japplphysiol.00182.2010a","volume":"109","author":"LG Navar","year":"2010","unstructured":"Navar LG. Counterpoint: Activation of the intrarenal renin-angiotensin system is the dominant contributor to systemic hypertension. J Appl Physiol. 2010;109(6):1998\u20132000.","journal-title":"J Appl Physiol"},{"issue":"1","key":"754_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1152\/physrev.00045.2011","volume":"93","author":"JM Forbes","year":"2013","unstructured":"Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137\u201388.","journal-title":"Physiol Rev"},{"issue":"4","key":"754_CR16","first-page":"S57","volume":"4","author":"JE Hall","year":"1986","unstructured":"Hall JE, Granger JP, Hester RL, Montani JP. Mechanisms of sodium balance in hypertension: role of pressure natriuresis. J Hypertens Suppl. 1986;4(4):S57-65.","journal-title":"J Hypertens Suppl"},{"issue":"1","key":"754_CR17","volume":"148","author":"KM Alexander","year":"2023","unstructured":"Alexander KM, Ersboell AS, Haase CL, Mortensen JT, Maurer MS. Abstract 13090: clinical burden of transthyretin amyloid cardiomyopathy (ATTR-CM) in the USA from 2004 to 2022. Circulation. 2023;148(1):A13090-A.","journal-title":"Circulation"},{"issue":"18","key":"754_CR18","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1093\/cvr\/cvac119","volume":"118","author":"A Porcari","year":"2023","unstructured":"Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovasc Res. 2023;118(18):3517\u201335.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"754_CR19","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/ejhf.2776","volume":"25","author":"A Porcari","year":"2023","unstructured":"Porcari A, Razvi Y, Masi A, Patel R, Ioannou A, Rauf MU, et al. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2023;25(4):515\u201324.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"754_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.14797\/mdcvj.1066","volume":"18","author":"CA Obi","year":"2022","unstructured":"Obi CA, Mostertz WC, Griffin JM, Judge DP. ATTR epidemiology, genetics, and prognostic factors. Method Debakey Cardiovasc J. 2022;18(2):17\u201326.","journal-title":"Method Debakey Cardiovasc J"},{"issue":"9","key":"754_CR21","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1002\/ejhf.2589","volume":"24","author":"AS Antonopoulos","year":"2022","unstructured":"Antonopoulos AS, Panagiotopoulos I, Kouroutzoglou A, Koutsis G, Toskas P, Lazaros G, et al. Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis. Eur J Heart Fail. 2022;24(9):1677\u201396.","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"754_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-089783","volume":"14","author":"M Guppy","year":"2024","unstructured":"Guppy M, Thomas ET, Glasziou P, Clark J, Jones M, O\u2019Hara DV, et al. Rate of decline in kidney function with age: a systematic review. BMJ Open. 2024;14(11):e089783.","journal-title":"BMJ Open"},{"issue":"10","key":"754_CR23","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1681\/ASN.2017040421","volume":"28","author":"MS Hommos","year":"2017","unstructured":"Hommos MS, Glassock RJ, Rule AD. Structural and functional changes in human kidneys with healthy aging. J Am Soc Nephrol. 2017;28(10):2838\u201344.","journal-title":"J Am Soc Nephrol"},{"issue":"22","key":"754_CR24","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1056\/NEJMra2201153","volume":"386","author":"AS Levey","year":"2022","unstructured":"Levey AS, Grams ME, Inker LA. Uses of GFR and albuminuria level in acute and chronic kidney disease. N Engl J Med. 2022;386(22):2120\u20138.","journal-title":"N Engl J Med"},{"issue":"11 Suppl 3","key":"754_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1524-6175.2004.4064.x","volume":"6","author":"RD Toto","year":"2004","unstructured":"Toto RD. Microalbuminuria: definition, detection, and clinical significance. J Clin Hypertens (Greenwich). 2004;6(11 Suppl 3):2\u20137.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"3","key":"754_CR26","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/ndt\/18.3.532","volume":"18","author":"L Lobato","year":"2003","unstructured":"Lobato L, Beir\u00e3o I, Silva M, Bravo F, Silvestre F, Guimar\u00e3es S, et al. Familial ATTR amyloidosis: microalbuminuria as a predictor of symptomatic disease and clinical nephropathy. Nephrol Dial Transplant. 2003;18(3):532\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"754_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/ejhf.3094","volume":"26","author":"A Ioannou","year":"2024","unstructured":"Ioannou A, Rauf MU, Patel RK, Razvi Y, Porcari A, Martinez-Naharro A, et al. Albuminuria in transthyretin cardiac amyloidosis: prevalence, progression and prognostic importance. Eur J Heart Fail. 2024;26(1):65\u201373.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"754_CR28","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1097\/00005344-199900001-00004","volume":"33","author":"G Maschio","year":"1999","unstructured":"Maschio G, Alberti D, Locatelli F, Mann JF, Motolese M, Ponticelli C, et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. J Cardiovasc Pharmacol. 1999;33(1):S16-20 (discussion S41-3).","journal-title":"J Cardiovasc Pharmacol."},{"issue":"2","key":"754_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1056\/NEJMoa053107","volume":"354","author":"FF Hou","year":"2006","unstructured":"Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354(2):131\u201340.","journal-title":"N Engl J Med"},{"issue":"15","key":"754_CR30","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"7","key":"754_CR31","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"23","key":"754_CR32","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"24","key":"754_CR33","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022859","volume":"10","author":"RK Cheng","year":"2021","unstructured":"Cheng RK, Vasbinder A, Levy WC, Goyal P, Griffin JM, Leedy DJ, et al. Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis. J Am Heart Assoc. 2021;10(24):e022859.","journal-title":"J Am Heart Assoc"},{"issue":"30","key":"754_CR34","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799\u2013806.","journal-title":"Eur Heart J"},{"issue":"3","key":"754_CR35","first-page":"424","volume":"36","author":"F Cappelli","year":"2020","unstructured":"Cappelli F, Martone R, Gabriele M, Taborchi G, Morini S, Vignini E, et al. Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems. Can J Cardiol. 2020;36(3):424\u201331.","journal-title":"Can J Cardiol"},{"issue":"9","key":"754_CR36","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1002\/ejhf.3354","volume":"26","author":"C Nitsche","year":"2024","unstructured":"Nitsche C, Ioannou A, Patel RK, Razvi Y, Porcari A, Rauf MU, et al. Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis. Eur J Heart Fail. 2024;26(9):2008\u201312.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"754_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/biom15010041","volume":"15","author":"M \u00c1vila","year":"2025","unstructured":"\u00c1vila M, Mora S\u00e1nchez MG, Bernal Amador AS, Paniagua R. The Metabolism of Creatinine and Its Usefulness to Evaluate Kidney Function and Body Composition in Clinical Practice. Biomolecules. 2025;15(1):41.","journal-title":"Biomolecules."},{"issue":"10","key":"754_CR38","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.34067\/KID.0003202022","volume":"3","author":"DC Chen","year":"2022","unstructured":"Chen DC, Potok OA, Rifkin D, Estrella MM. Advantages, limitations, and clinical considerations in using cystatin C to estimate GFR. Kidney360. 2022;3(10):1807\u201314.","journal-title":"Kidney360"},{"issue":"8","key":"754_CR39","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3390\/brainsci11080980","volume":"11","author":"PM Ferraro","year":"2021","unstructured":"Ferraro PM, D\u2019Ambrosio V, Di Paolantonio A, Guglielmino V, Calabresi P, Sabatelli M, et al. Renal Involvement in Hereditary Transthyretin Amyloidosis: An Italian Single-Centre Experience. Brain Sci. 2021;11(8):980.","journal-title":"Brain Sci."},{"issue":"2","key":"754_CR40","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/ckj\/sfac156","volume":"16","author":"V D'Ambrosio","year":"2023","unstructured":"D\u2019Ambrosio V, Ferraro PM, Guglielmino V, Luigetti M. Kidney involvement in hereditary transthyretin amyloidosis: is there a role for cystatin C? Clin Kidney J. 2023;16(2):397\u20138.","journal-title":"Clin Kidney J"},{"key":"754_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2025.112930","volume":"141","author":"AAK Korovesi","year":"2026","unstructured":"Korovesi AAK, Pateli A, Kastritis E, Poulia KA, Stamatelopoulos K, Karatzi K. Diet-related poor nutritional status as a major challenge in the treatment of patients with amyloidosis: a systematic review. Nutrition. 2026;141:112930.","journal-title":"Nutrition"},{"key":"754_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10153415","author":"A Broussier","year":"2021","unstructured":"Broussier A, David JP, Kharoubi M, Oghina S, Segaux L, Teiger E, et al. Frailty in wild-type transthyretin cardiac amyloidosis: the tip of the iceberg. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10153415.","journal-title":"J Clin Med"},{"issue":"1","key":"754_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-69123-x","volume":"14","author":"M Luigetti","year":"2024","unstructured":"Luigetti M, Vitali F, Romano A, Sciarrone MA, Guglielmino V, Ardito M, et al. Emerging multisystem biomarkers in hereditary transthyretin amyloidosis: a pilot study. Sci Rep. 2024;14(1):18281.","journal-title":"Sci Rep"},{"issue":"12","key":"754_CR44","first-page":"995","volume":"126","author":"D Fedak","year":"2016","unstructured":"Fedak D, Ku\u017aniewski M, Fugiel A, Wieczorek-Surdacka E, Przepi\u00f3rkowska-Hoyer B, Jasik P, et al. Serum uromodulin concentrations correlate with glomerular filtration rate in patients with chronic kidney disease. Pol Arch Med Wewn. 2016;126(12):995\u20131004.","journal-title":"Pol Arch Med Wewn"},{"issue":"10","key":"754_CR45","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003011","volume":"95","author":"D Steubl","year":"2016","unstructured":"Steubl D, Block M, Herbst V, Nockher WA, Schlumberger W, Satanovskij R, et al. Plasma uromodulin correlates with kidney function and identifies early stages in chronic kidney disease patients. Medicine (Baltimore). 2016;95(10):e3011.","journal-title":"Medicine (Baltimore)"},{"issue":"42","key":"754_CR46","doi-asserted-by":"publisher","first-page":"4379","DOI":"10.1093\/eurheartj\/ehaf591","volume":"46","author":"LA Inker","year":"2025","unstructured":"Inker LA, Neuen BL, McCallum W, Vaduganathan M, Greene T, Heerspink HJL. Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions. Eur Heart J. 2025;46(42):4379\u201395.","journal-title":"Eur Heart J"},{"issue":"3","key":"754_CR47","first-page":"A4362795-A","volume":"152","author":"F Sheikh","year":"2025","unstructured":"Sheikh F, Dang J, Fontana M, Audard V, Garcia-Pavia P, Khouri M, et al. Abstract Vutrisiran Improved Outcomes Versus Placebo in Patients with Transthyretin Amyloidosis with Cardiomyopathy and Severe Chronic Kidney Disease Post Hoc Analysis of HELIOS-B. Circulation. 2025;152(3):A4362795-A.","journal-title":"Circulation"},{"issue":"7","key":"754_CR48","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jacc.2024.10.097","volume":"85","author":"M Fontana","year":"2025","unstructured":"Fontana M, Maurer MS, Gillmore JD, Bender S, Jay PY, Solomon SD. Worsening of heart failure in outpatients with transthyretin amyloidosis and cardiomyopathy in the APOLLO-B trial. J Am Coll Cardiol. 2025;85(7):744\u201352.","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"754_CR49","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","volume":"83","author":"A Porcari","year":"2024","unstructured":"Porcari A, Cappelli F, Nitsche C, Tomasoni D, Sinigiani G, Longhi S, et al. SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2024;83(24):2411\u201322.","journal-title":"J Am Coll Cardiol"},{"key":"754_CR50","doi-asserted-by":"crossref","unstructured":"Nies RJ, Ney S, Nies JF, Seuthe K, Kl\u00f6sges L, Br\u00fcwer M, et al. Outpatient diuretic intensification: a simple prognostic marker in cardiac transthyretin amyloidosis. Clin Res Cardiol. 2025.","DOI":"10.1007\/s00392-025-02617-4"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-026-00754-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-026-00754-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-026-00754-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:02:13Z","timestamp":1774526533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-026-00754-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["754"],"URL":"https:\/\/doi.org\/10.1007\/s11897-026-00754-z","relation":{},"ISSN":["1546-9549"],"issn-type":[{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Dr. Grodin reports personal fees from Pfizer, Alnylam, Eidos\/BridgeBio, AstraZeneca, Alexion, Lumanity, Novo Nordisk, Ultromics, Intellia, and Tenax Therapeutics, and grant support from NHLBI (R01HL160892 and R01HL172993), Pfizer (67656485), Eidos\/BridgeBio, and Texas Health Resources Clinical Scholars Fund[LR1.1][BR1.2]. Dr. Toto reports serving on Data Monitoring Committees for AstraZeneca and Alnlyam. He is also a site principal investigator for Vertex Pharma clinical trial and grant support from NIH. Bethany Roehm reports consulting fees from Revamp Medical. Lori Roth reports consulting fees from Eidos\/BridgeBio and Alnylam.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}